Fig. 6
From: The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Prediction of BH3-mimetic responses. Linear regression analyses between cancer cell line response to BH3-mimetics from the PRISM Drug Repurposing Library and BCL2 RNA interference (green), BCL2 dependence score (pink) and BCL2 gene expression (blue). a Linear regression analyses between response to ABT-199 (venetoclax) and BCL2 (myeloid and lymphoid malignancies were not included in PRISM repurposing screening for ABT-199). b Linear regression analyses between response to ABT-263 (navitoclax) and BCL2. c Linear regression analyses between response to ABT-263 (navitoclax) and BCL2L1/BCL-XL. d Linear regression analyses between response to S63845 and MCL1. The most significant correlation is a negative one between BCL2L1 expression and navitoclax response (c), however the R-squared value is only 0.06
